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A New Origin for Chartreusin
Unraveling the sequence of reactions that transforms
caromatic polyketide backbones into much more elab-
porate structures, for example the chartreusin bislac-
btone, is challenging, but in this issue of Chemistry &
tBiology, Xu and coworkers [1] show that sequencing
the gene clusters can provide valuable clues.
t
tAromatic polyketides are a structurally rich group of
dnatural products that exhibit a wide range of valuable
fbiological activities; notable members include the anti-
pbiotic tetracycline, the anticancer drug doxorubicin,
wand the estrogen receptor agonist R1128. Despite their
tdiversity, aromatic polyketides are all assembled from
ssimple small-molecule precursors (most often acetate)
mby multienzyme complexes called type II polyketide
msynthases (PKSs). These assemblies minimally include
fan enzyme for joining the building blocks into long
achains (ketosynthase α, KSα), and a noncatalytic pro-
mtein to which the growing chain is tethered (acyl carrier
cprotein [ACP]) (Figures 1A and 1B) [2]. This “minimal
aPKS” also incorporates an enzyme, KSβ or chain length
vfactor, whose precise role is the subject of some dis-
opute, but which has been implicated both in the provi-
sion of starter units [3] and the control of chain length e4]. Together, these domains iterate through multiple
ycles of chain extension to form a polyketone of a
pecific length, which is then modified by a suite of
ccessory PKS enzymes including ketoreductases, cy-
lases, and aromatases into a polycyclic, aromatic
roduct [5]. Post-PKS elaboration of these structures
y, for example, oxidation, methylation, and glycosyla-
ion, results in the bioactive compounds.
Considerable progress has been made in redirecting
he biosynthesis of aromatic polyketides to the forma-
ion of novel compounds by mixing and matching PKS
omains through genetic engineering, a concept re-
erred to as “combinatorial biosynthesis” [6]. Early ex-
eriments relied on an empirical set of “design rules”
hich guided the choice of domains to combine to ob-
ain a particular synthetic outcome [7]. More recent
tudies, however, have begun to illuminate some of the
echanistic and structural aspects of type II PKS do-
ains that influence the choice of starter unit [8], the
inal chain length, and the mechanisms of chain folding
nd cyclization [9–11], opening the way to rationally
anipulating these features. However, a significant
ontribution to the structural diversity and biological
ctivity of some aromatic polyketides comes from the
ariable, and often complex, post-PKS rearrangement
f the initially formed skeleton by so-called “tailoring”
nzymes [12]. Yet here our knowledge both of the se-
Previews
513quence of reactions and the mechanistic basis for
these transformations is more limited, which has an im-
pact on our ability to manipulate these critical events.
A classic approach to determining the order of post-
PKS processing reactions is to add 13C-doubly-labeled
acetate to the culture medium of the producing organ-
ism, such that each molecule of the target polyketide
contains a single molecule of labeled precursor [6]. By
NMR analysis, it is then possible to identify sites at
which acetate had been incorporated intact into the
polyketide backbone, and also positions where some
rearrangement process had resulted in cleavage of the
acetate carbon-carbon bond. These results are then
used to construct a plausible mechanism by which the
chain is folded and then subsequently reorganized into
the final product. Such theories can gain significant
credibility when one of the proposed intermediates in
the biosynthesis is then isolated from a “blocked mu-
tant” of the producing strain, in which one of the steps
in the pathway has been disabled [13].
The aromatic polyketide chartreusin (Figure 2) has been
the object of speculations aimed at elucidating the bio-
synthetic pathway to its unusual bislactone aglycone,
called chartarin. Pharmacological studies have demon-
strated that the bislactone system is critical for the high
antitumor activity of chartreusin [14], and so it is a very
attractive target for modification by both genetic engi-
neering and semisynthesis. Experiments in the 1970s
with 13C-acetate yielded a labeling pattern that was
difficult to reconcile with models of polyketide folding
and cyclization, but nonetheless, it was proposed that
chartreusin derives from an initially formed polyketide
undecaketide, which is substantially rearranged by aFigure 1. Reactions of the Minimal Polyke-
tide Synthase in the Assembly of Aromatic
Polyketides
(A) Biosynthesis is initiated by decarboxyl-
ation of acyl carrier protein (ACP) bound mal-
onate to yield acetyl-ACP, in a reaction cata-
lyzed by either ketosynthase α (KSα) or KSβ.
The acetate is then transferred to the active
site cysteine of the KSα domain.
(B) The biosynthesis continues with transfer
of the extender unit malonate to the ACP.
The KSα domain then catalyzes decarboxy-
lative condensation to yield a diketide at-
tached to the ACP. The extended chain is
passed back to the KSα domain, and the cy-
cle continues until a chain of the appropriate
length is synthesized.series of oxidative reactions to yield the final bislactone
product [15, 16]. However, this mechanistic scheme could
not explain why a mutant strain of the chartreusin pro-
ducer Streptomyces chartreusis should produce a me-
tabolite, chrymutasin, whose structure is consistent with
originating instead from a decaketide [17].
A more modern strategy for investigating metabolic
pathways is to clone and sequence the biosynthetic
genes. Gene clusters for type II aromatic polyketides
can usually be located within genomic libraries by PCR
screening using degenerate probes designed against
the well-conserved sequences of the KSα domains.
In this way, Xu and colleagues were able to identify in
S. chartreusis, a putative ca. 37 kb gene cluster for
chartreusin production [1]. To confirm its role in the bio-
synthesis, they expressed the gene set in the heterolo-
gous host Streptomyces albus and obtained a fluores-
cent metabolite that was identical to chartreusin by
chromatographic and mass spectrometric analysis.
In the center of the cluster they identified, as antici-
pated, genes for the minimal PKS components, KSα,
KSβ, and ACP. However, the closest homologs to the KS
genes in the sequence databases were from clusters
involved in the biosynthesis of decaketides, and not
those directing the assembly of longer polyketide
chains. Critically, this finding implied that chartreusin
must originate from a decaketide and not an undecake-
tide, and therefore that the proposed pathway to its
biosynthesis needed substantial revision. To gain sup-
port for their hypothesis, Xu et al. inactivated a gene
within the cluster, chaZ, a putative FAD-dependent
monooxygenase which they suspect initiates the reor-
ganization of the polyketide skeleton by a Baeyer-Vil-
Chemistry & Biology
514S
liger-type oxidation. As hoped, the strain accumulated
a simpler metabolite, resomycin C—a decaketide. Al-
though for technical reasons the authors could not
demonstrate unequivocally that resomycin C is a true
intermediate in the pathway (and not simply an aberrant
shunt product), taken together, the sequence and
structural data show that chartreusin is derived from a
decaketide progenitor and not an undecaketide.
Inspiration for constructing a new pathway from res-
omycin C to the chartarin bislactone that is also consis-
tent with the original 13C-labeling studies comes from
the gene cluster. In addition to chaZ, the authors found
a gene, chaP, for a putative dioxygenase; ChaP is a
member of the vicinal oxygen chelate (VOC) superfam-
ily, which catalyzes a variety of reactions including oxi-
dative cleavage of C-C bonds [18]. In their new biosyn- 1
thetic scheme, ChaZ and ChaP perform two as yet
1unprecedented C-C bond cleavage reactions, which
play critical roles in rearranging the polyketide skeleton
1
from the chartarin aglycone. The results of experiments
designed to prove this rearrangement cascade by elu- 1
cidating all of the pathway intermediates are eagerly
1anticipated, as are mechanistic studies of these fasci-
nating tailoring enzymes. 1
Chartreusin suffers from poor pharmacokinetics, but
1its biological activity can be improved by modifying its
disaccharide moiety (Figure 2). For example, a natural
1derivative of chartreusin, elsamicin A, incorporates an
amino sugar in place of digitalose and exhibits in- 1
1creased water solubility [19]. With heterologous expres-
sion in S. albus established, it should be possible to
obtain the chartarin aglycone from an appropriately en-
2
gineered blocked mutant. The aglycone could then be
used to construct a library of chartreusin analogs withm
s
s
t
t
t
t
s
i
K
D
U
8Figure 2. Structure of the Aromatic Polyketide Chartreusin
CChartreusin incorporates an unusual bislactone skeleton and a di-
Usaccharide consisting of fucose and digitalose.odified patterns of glycosylation. Sequencing has
hown that the cluster contains two putative glyco-
yltransferases, ChaGT1 for attachment of fucose to
he chartarin aglycone, and ChaGT2, which catalyzes
he unprecedented 2-glycosylation of fucose with digi-
alose. If these enzymes exhibit the broad specificity
oward the sugar donor observed for other glyco-
yltransferases from PKS systems [20], they could be
nvaluable for chartreusin drug discovery efforts.
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